Trasylol prevents trypsin-induced shock in dogs

Area of Science:

• Pharmacokinetics
• Protease Inhibitor Interactions
• Biochemistry

Background:

• Plasma protease inhibitors, specifically alpha1-antitrypsin and alpha-macroglobulins, play a crucial role in regulating proteolytic activity.
• Understanding the dynamics of protease-inhibitor interactions is vital for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the pharmacokinetic behavior of Trasylol and its interaction with bovine trypsin in dogs.
• To elucidate the roles of alpha1-antitrypsin and alpha-macroglobulins in binding trypsin and Trasylol complexes.

Main Methods:

• Intravenous administration of bovine trypsin and Trasylol in dogs.
• Continuous infusion of Trasylol.
• Monitoring the plasma levels and complex formation of trypsin, Trasylol, alpha1-antitrypsin, and alpha-macroglobulins.

Main Results:

• Bovine trypsin preferentially binds to alpha-macroglobulins, even in the presence of Trasylol.
• Alpha1-antitrypsin binds significant amounts of trypsin upon saturation of alpha-macroglobulins.
• Trasylol forms complexes with trypsin-alpha-macroglobulin complexes and is rapidly cleared.
• Free Trasylol and Trasylol-trypsin complexes appear when alpha-macroglobulins are saturated, suggesting complex transfer.

Conclusions:

• Alpha-macroglobulins are the primary scavengers for administered trypsin.
• Trasylol's elimination is linked to its complexation with trypsin, particularly within alpha-macroglobulin complexes.
• The interplay between trypsin, Trasylol, and plasma protease inhibitors influences Trasylol's pharmacokinetics and efficacy.